154 related articles for article (PubMed ID: 8339212)
21. Long-term interferon therapy for thrombocytosis in myeloproliferative diseases.
Gisslinger H; Ludwig H; Linkesch W; Chott A; Fritz E; Radaszkiewicz T
Lancet; 1989 Mar; 1(8639):634-7. PubMed ID: 2564458
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic thrombocytapheresis for extreme thrombocytosis after chemotherapy in essential thrombocytosis.
Almeida-Dias R; Garrote M; Cid J; Mustieles MJ; Alba C; Lozano M
J Clin Apher; 2019 Aug; 34(4):503-506. PubMed ID: 30624802
[TBL] [Abstract][Full Text] [Related]
23. Plateletpheresis in the management of thrombocytosis.
Taft EG; Babcock RB; Scharfman WB; Tartaglia AP
Blood; 1977 Nov; 50(5):927-33. PubMed ID: 907841
[TBL] [Abstract][Full Text] [Related]
24. [Interferon in the eradication of the Philadelphia chromosome in chronic myeloid leukemia].
Arana-Trejo RM; Ovilla-Martínez R; Gómez-Morales E; Meillon-García L; Cervantes-Peredo A; González-Llaven J; Pizzuto-Chávez J; Kofman-Alfaro S
Rev Invest Clin; 1997; 49(3):209-14. PubMed ID: 9380976
[TBL] [Abstract][Full Text] [Related]
25. [Therapy of thrombocytosis in myeloproliferative syndromes using recombinant interferon-alpha-2a].
Tichelli A; Gratwohl A; Delacrétaz F; Dazzi H; Stebler C; Wernli M; Holdener EE; Nissen C; Speck B
Schweiz Med Wochenschr; 1989 Sep; 119(39):1347-52. PubMed ID: 2799342
[TBL] [Abstract][Full Text] [Related]
26. The combined use of hydroxyurea and anagrelide allows satisfactory hematologic control in patients with chronic myeloproliferative disorders and thrombocytosis: a report on 13 patients with poor tolerance to hydroxyurea monotherapy.
D'adda M; Micheletti M; Drera M; Ferrari S; Rossi G
Leuk Lymphoma; 2008 Nov; 49(11):2216-8. PubMed ID: 19021067
[No Abstract] [Full Text] [Related]
27. Thrombocytosis in myelodysplastic and myelodysplastic/myeloproliferative syndromes.
Kodali D; Mesa H; Rawal A; Cao Q; Gupta P
Leuk Lymphoma; 2007 Dec; 48(12):2375-80. PubMed ID: 18067013
[TBL] [Abstract][Full Text] [Related]
28. Treatment of thrombocytosis in myeloproliferative disorders with interferon alpha-2a.
Tichelli A; Gratwohl A; Berger C; Lori A; Würsch A; Dieterle A; Thomssen C; Nissen C; Holdener E; Speck B
Blut; 1989 Jan; 58(1):15-9. PubMed ID: 2644994
[TBL] [Abstract][Full Text] [Related]
29. [Alfa-2b interferon in the treatment of thrombocytosis associated to chronic non leukemic myeloproliferative syndromes].
Petit J; Callís M; Domingo Albós A; Fernández de Sevilla A; Besses C; Martí JM
Med Clin (Barc); 1993 Nov; 101(16):601-3. PubMed ID: 8271861
[TBL] [Abstract][Full Text] [Related]
30. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C
Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691
[TBL] [Abstract][Full Text] [Related]
31. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
Nielsen I; Hasselbalch HC
Am J Hematol; 2003 Sep; 74(1):26-31. PubMed ID: 12949887
[TBL] [Abstract][Full Text] [Related]
32. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders.
Randi ML; Ruzzon E; Luzzatto G; Tezza F; Girolami A; Fabris F
Haematologica; 2005 Feb; 90(2):261-2. PubMed ID: 15710584
[TBL] [Abstract][Full Text] [Related]
33. The biology and treatment of chronic myelogenous leukemia.
Brunstein CG; Mcglave PB
Oncology (Williston Park); 2001 Jan; 15(1):23-31; discussion 31-2, 35. PubMed ID: 11271979
[TBL] [Abstract][Full Text] [Related]
34. Successful treatment of accelerated and blastic phase of chronic myeloid leukemia with high-dose interferon alpha and hydroxyurea: a novel approach.
Jehn U; Pötscher C; Heinemann V
Leuk Lymphoma; 1995 Sep; 19(1-2):153-7. PubMed ID: 8574162
[TBL] [Abstract][Full Text] [Related]
35. The management of elderly patients with myeloproliferative disorders.
Tura S
Hematol Oncol; 1993; 11 Suppl 1():39-41. PubMed ID: 8486340
[No Abstract] [Full Text] [Related]
36. [The treatment of myeloproliferative syndromes].
Maurice P
Schweiz Med Wochenschr; 1975 Oct; 105(40):1269-74. PubMed ID: 1061995
[TBL] [Abstract][Full Text] [Related]
37. Management of thrombocytosis.
Taft EG
Transfusion; 1980; 20(2):235-6. PubMed ID: 7368272
[No Abstract] [Full Text] [Related]
38. Immunotherapy for chronic myelogenous leukemia: survival not affected by treatment in the stable phase.
Baker MA; Taub RN; Carter WH; Davidson M; Sutton DM; Kutas G; Berger S; Watt HJ
Cancer Res; 1984 Jan; 44(1):383-5. PubMed ID: 6360347
[TBL] [Abstract][Full Text] [Related]
39. Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; Kurzrock R; Keating MJ; McCredie KB; Gutterman J; Freireich EJ
Acta Haematol; 1987; 78 Suppl 1():70-4. PubMed ID: 2449026
[TBL] [Abstract][Full Text] [Related]
40. Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survival.
Olsson-Strömberg U; Simonsson B; Ahlgren T; Björkholm M; Carlsson K; Gahrton G; Hast R; Löfvenberg E; Linder O; Ljungman P; Malm C; Paul C; Rödjer S; Turesson I; Udén AM; Wahlin A; Killander A; Wadman B; Westin J; Vikrot O; Zettervall O; Oberg G;
Hematol J; 2004; 5(6):462-6. PubMed ID: 15570285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
